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ISObjective: The presence of minority nonnucleoside reverse transcriptase inhibitor
(NNRTI)-resistant HIV-1 variants prior to antiretroviral therapy (ART) has been linked
to virologic failure in treatment-naive patients.
Design: We performed a large retrospective study to determine the number of treat-
ment failures that could have been prevented by implementing minority drug-resistant
HIV-1 variant analyses in ART-naı¨ve patients in whom no NNRTI resistance mutations
were detected by routine resistance testing.
Methods: Of 1608 patients in the Swiss HIV Cohort Study, who have initiated first-line
ARTwith two nucleoside reverse transcriptase inhibitors (NRTIs) and one NNRTI before
July 2008, 519 patients were eligible by means of HIV-1 subtype, viral load and sample
availability. Key NNRTI drug resistance mutations K103N and Y181C were measured
by allele-specific PCR in 208 of 519 randomly chosen patients.
Results: Minority K103N and Y181C drug resistance mutations were detected in five
out of 190 (2.6%) and 10 out of 201 (5%) patients, respectively. Focusing on 183
patients for whom virologic success or failure could be examined, virologic failure
occurred in seven out of 183 (3.8%) patients; minority K103N and/or Y181C variants
were present prior to ART initiation in only two of those patients. The NNRTI-contain-
ing, first-line ART was effective in 10 patients with preexisting minority NNRTI-resistant
HIV-1 variant.
Conclusion: As revealed in settings of case–control studies, minority NNRTI-resistant
HIV-1 variants can have an impact on ART. However, the sole implementation of
minority NNRTI-resistant HIV-1 variant analysis in addition to genotypic resistanceippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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The HIV type 1 (HIV-1) establishes a chronic infection
that is incurable to date. Combination antiretroviral
therapy (ART) substantially decreases the morbidity and
mortality in HIV-1 infected patients [1]. To achieve this
outcome, the majority of patients have to be treated
lifelong. This goes along with the risk of virologic failure
and development of drug resistance that limits further
treatment options [2,3]. Furthermore, as drug-resistant
viruses can be transmitted, it is recommended to test for
the presence of drug resistance mutations before initiating
ART in treatment-naive patients [4].Routine genotypic resistance testing based on population
sequencing (GRT) misses minority drug-resistant HIV-1
variants representing less than 20–25% of the virus
population [5–7]. The application of more sensitive
technologies to detect and quantify minority drug-
resistant HIV-1 variants has revealed that these low
abundant viruses can cause virologic failure especially in
the context of ART regimens with a low genetic barrier
to resistance, for instance, nonnucleoside reverse tran-
scriptase inhibitor (NNRTI)-containing regimens [8–
11]. A pooled analysis of 10 studies and almost 1000
patients has shown that preexisting minority NNRTI-
resistant HIV-1 variants are associated with virologic
failure [9]. A recent European multicohort case–control
study [11] of 368 individuals using centralized ultra-
sensitive 454 sequencing showed a significantly increased
risk of virologic failure to first-line NNRTI-based ART
when minority drug-resistant HIV-1 variants preexisted.
These studies were designed as case–control or cohort
studies focusing on patients experiencing virologic failure
[9].Current antiretroviral regimens are very efficient and the
number of virologic failures due to drug resistance is low
in ART-naive patients. However, to minimize this risk of
virologic failure of first-line ART even further, it is
currently discussed to implement more sensitive geno-
typic resistance testing in routine clinical settings to detect
systematically preexisting minority drug-resistant HIV-1
variants. To answer this, we have designed a study
composed of a representative group of patients from the
nation-wide, observational Swiss HIV Cohort Study
(SHCS). Patients selected for inclusion were ART-naive,pincott Williams & Wilkins. Unauthostarted with a NNRTI-containing ARTand in whom no
NNRTI or NRTI resistance mutation was detected by
routine GRT prior to ART. Minority drug-resistant
HIV-1 variants were measured and analysed in the
context of virologic success or failure.Materials and methods
Study participants and study design
The SHCS is an observational, nation-wide cohort,
including at least 45% of the cumulative number of HIV-1
infected individuals declared to the Swiss health
authorities [12]. The inclusion criteria for this substudy
were as follows: chronic infection with HIV-1 subtype B
or 01_AE, start of first-line ART with NNRTI and two
NRTIs before 1 July 2008, no NNRTI or NRTI
resistance mutations prior to ART detected by population
sequencing, baseline viral load above 1000 HIV-1 RNA
copies/ml plasma and available plasma sample within 6
months before initiation of first-line ART.
Random selection was performed within strata of HIV-1
subtype and time periods (4-year intervals of estimated
year of HIV-1 infection between 1980 and 2008; time
band sampling). The number of samples per stratum was
selected proportionally to the fraction observed in all
eligible patients. The infection date was estimated
according to the method developed by P. Taffe´ and M.
May [13]. The SHCS has been approved by ethical
committees from all participating institutions and written
informed consent has been obtained from all individuals
[12].
Twenty-four months follow-up data were used to
differentiate two groups of patients: those who experi-
enced virologic failure and those who were successfully
treated. Virologic failure was defined as virologic rebound
with two consecutive viral loads more than 200 HIV-1
RNA copies/ml plasma after having achieved a viral load
less than 50 copies/ml after initiation of first-line ARTor
one viral load of more than 200 HIV-1 RNA copies/ml
plasma after 6–24 months of continuous treatment,
followed by a modification of treatment or as virologic
nonresponse, that is failing to achieve a decrease in viral
load less than 200 HIV-1 RNA copies/ml plasma within
16 weeks of continuous treatment.rized reproduction of this article is prohibited.
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real-time PCR
Plasma HIV-1 viral load was quantified and genotypic
resistance testing by population sequencing was per-
formed as described [14]. Drug resistance mutations were
defined as recommended by the International Antiviral
Society-USA (IAS-USA) Drug Resistance Mutations
Group and the surveillance drug resistance mutations list
[2,15]. Minority K103N, Y181C and M184V drug-
resistant HIV-1 variants were quantified by allele-specific
real-time PCRs (AS-PCRs) as previously described in
detail [10,14,16–18]. Each AS-PCR has a dynamic range
of six logs and a detection limit of 10 HIV-1 DNA copies
per reaction. The discriminatory abilities are as follows:
0.01% for the K103N, 0.2% for the Y181C and M184V
mutations. Mutational load was calculated by multiplying
the percentage of a given minority drug-resistant HIV-1
variant with the viral load.
Data and statistical analyses
Clinical data from the SHCS were used as well as HIV-1
pol sequences from the SHCS drug resistance database,
which are stored in SmartGene’s Integrated Database
Network System (IDNS version 3.6.6) [19]. Statistical
analyses were performed with Stata 12 SE software
(StataCorp). All P values were two-sided, and the level of
significance was set at 0.05.Copyright © Lippincott Williams & Wilkins. Unaut
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Baseline characteristics
The SHCS comprised 15 857 participants on 30 June
2010. One thousand six hundred and eight participants
were chronically HIV-1 infected, ART-naive and started
first-line ART containing one NNRTI and two NRTIs
before 1 July 2008 (Fig. 1). Another inclusion criterion
was the infection with HIV-1 subtype B or 01_AE, which
was necessary, because the AS-PCR primer design is only
optimal for those two subtypes. For other HIV-1
subtypes, individual confirmation of the homology of
primer binding sites would have been necessary that could
potentially have jeopardized the random selection of
patients. As shown in Fig. 1, 519 patients were deemed
eligible for this study, of whom 221 individuals were
randomly selected for minority drug-resistant HIV-1
variant testing. Finally, data from 208 patients were
included in the analysis. Thirteen exclusions were due to
sample unavailability, previously not reported NNRTI or
NRTI resistance in the majority of viruses, or
unsuccessful RT-PCR (Fig. 1).
These 208 patients were representative of all 519 eligible
patients, thus representing chronically HIV-1 subtype
B or 01_AE infected patients in Switzerland receiving
first-line, NNRTI-containing ART. No significanthorized reproduction of this article is prohibited.
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4 AIDS 2014, Vol 00 No 00differences were observed in terms of age, sex, ethnicity,
route of transmission, estimated year of HIV-1 infection,
CD4þ cell count and viral load at baseline, and first-line
ART regimens (Table 1). It has to be noted that certain
clinical parameters differed significantly between the 519
eligible patients and the remaining 1089 of all 1608
patients who started first-line treatment with an NNRTI-
containing regimen. Due to the exclusion of almost all
HIV-1 non-B subtypes, these groups differed in terms of
sex distribution, transmission routes, ethnicity and,
naturally, HIV-1 subtype distribution (data not shown).
Patients who matched our inclusion criteria were
predominantly white MSM and were infected with
HIV-1 subtype B. Both groups did not differ in terms of
the rate of virologic failure, viral load prior to initiation of
ART and first-line NNRTI.
Low prevalence of preexisting minority
nonnucleoside reverse transcriptase inhibitor
resistant HIV-1 variants in antiretroviral therapy
naive patients in routine clinical settings and
missing association with virologic failure
Minority NNRTI-resistant HIV-1 variants were present
prior to first-line NNRTI-containing ART in 14 of 208
patients (6.7%). The K103N mutation was detected
in five out of 190 (2.6%) patients at frequencies of
0.08–7.46% (3 x <1%, 2 x >2%) and the Y181C
mutation in 10 out of 201 (5%) patients at frequencies ofpyright © Lippincott Williams & Wilkins. Unautho
Table 1. Baseline characteristics of randomized/tested patients and remai
usefulness of implementing more sensitive drug resistance assays in routi
Clinical parameter
Age, median (IQR), years
Sex, No. (%) Male
Female
Ethnicity, No. (%) White
Nonwhite
Route of transmission, MSM
No. (%) Het
IDU
HIV-1 subtype, B
No. (%) 01_AE
Estimated year of HIV-1
infection, median (IQR), years
1999 (1995–2001)
CD4þ cell count median
(IQR), cells/ml blood
218.5 (159.5–292)
HIV-1 viral load, median (IQR),
log10 HIV-1 RNA copies/ml plasma
4.9 (4.5–5.3)
start of first-line ART, median (IQR), years 2005 (2003–2007)
NNRTI, No. (%) EFV
NVP
NRTI, No. (%) AZT and 3TC
TDF and FTC
TDF and 3TC
ABC and 3TC
Others
Virologic outcome of first-line ART, No. (%) n¼183
Virologic success
Virologic failure
ABC, abacavir; AZT, zidovudine; 3TC, lamivudine; EFV, efavirenz; FTC, em
type 1; IDU, intravenous drug use; IQR, interquartile range; MSM, men wh
inhibitor; NRTI, nucleos/tide reverse transcriptase inhibitor; NVP, nevirapi0.5–2.7% (7 x<1%, 2 x 1–2%, 1 x>2%). Calculating the
mutational load, that is the total amount of HIV-1 RNA
copies/ml plasma carrying a drug resistance mutation, the
results were as follows: K103N: 104–20 579 (3 x <1000,
2 x >2000) and Y181C: 215–6489 (9 x <1000, 1
x >2000) mutant HIV-1 RNA copies/ml plasma. The
M184V mutation was verified in one of 205 (0.5%)
patients representing 0.9% of the virus population, that is
91 mutant HIV-1 RNA copies/ml plasma. Virus
replication was successfully suppressed in this patient.
For 183 of the 208 randomly chosen patients, virologic
success or failure could be examined, because 24 or more
months of follow-up was available. Twenty-five patients
were not eligible for this analysis due to the following
reasons: two patients died, two were lost to follow-up, 13
patients switched to another regimen due to side effects,
four patients decided to switch or stop treatment, and in
four patients the reason for discontinuation of treatment
was unknown; virological failure was not reported, and
two patients harboured the Y181C mutation as minority
variant.
Of those 183 patients, 176 patients (96.2%) were
virologically suppressed until month 24 while receiving
their first-line, NNRTI-containing regimen. Seven
patients (3.8%) experienced virologic failure as defined
in the Materials and Methods section (Table 1). Two ofrized reproduction of this article is prohibited.
ning patients of a total of 519 eligible patients in the investigation of
ne clinical settings.
Randomized/tested
patients (n¼208)
Not tested patients
(n¼311) P
39 (32–45) 39 (34–45) 0.159
170 (81.7) 263 (84.6) 0.395
38 (18.3) 48 (15.4)
188 (90.4) 279 (89.7) 0.802
20 (9.6) 32 (10.3)
114 (54.8) 178 (57.2) 0.841
67 (32.2) 93 (29.9)
27 (13.0) 40 (12.9)
198 (95.2) 292 (93.9) 0.527
10 (4.8) 19 (6.1)
1998 (1995–2001) 0.582
216 (150–308) 1
4.9 (4.4–5.2) 0.276
2005 (2002–2006) 0.086
180 (86.5) 275 (88.4) 0.522
28 (13.5) 36 (11.6)
73 (35.1) 135 (43.4) 0.295
61 (29.3) 86 (27.6)
31 (14.9) 44 (14.2)
21 (10.1) 21 (6.8)
22 (10.6) 25 (8.0)
n¼471
176 (96.2) 269 (93.4) 0.199
7 (3.8) 19 (6.6)
tricitabine; Het, heterosexual; HIV-1, human immunodeficiency virus
o have sex with men; NNRTI, nonnucleos/tide reverse transcriptase
ne; TDF, tenofovir.
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Limited benefit of more sensitive genotypic resistance testing Metzner et al. 5them harboured minority NNRTI-resistant HIV-1
variants prior to first-line ART (Fig. 2). In patient 8,
who failed with the exclusive selection of the M184I
mutation, 0.6% of the virus population carried the
Y181C mutation prior to ART. Patient 13, who
harboured both NNRTI mutations in high mutational
loads prior to ART, failed rapidly within the firstCopyright © Lippincott Williams & Wilkins. Unaut
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nevirapine; TDF, tenofovir.4 months, accompanied by the selection of K103N and
Y181C mutations (Fig. 2). For this patient, a likely
association existed between preexisting minority
NNRTI-resistant HIV-1 variants and virologic failure.
However, the virologic failures in the other five patients
cannot be explained by the preexistence of minority
K103N or Y181C HIV-1 variants. In contrast, anotherhorized reproduction of this article is prohibited.
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6 AIDS 2014, Vol 00 No 0010 patients harboured minority NNRTI-resistant HIV-1
variants prior to first-line ART without experiencing
virologic failure.
As the number of well defined virologic failures was low
(seven patients of whom just two harboured preexisting
minority NNRTI-resistant HIV-1 variants), we measured
minority NNRTI-resistant HIV-1 variants in additional
10 patients from the 19 not tested patients experiencing
virologic failure (Table 1). The K103N mutation was not
detected in any of those patients. The Y181C mutation
was detected in one of 10 patients prior to ART at a
frequency of 0.5%, that is 725 Y181C RNA copies/ml
plasma. This patient showed the following drug resistance
mutations during virologic failure: K65R, K103N,
Y181C and M184V. In total, three of 13 patients carrying
minority NNRTI-resistant HIV-1 variants prior to first-
line ART experienced virological failure, that is this
results in a positive predictive value for any of these
minority NNRTI resistance mutations of 23% meaning
that first-line, NNRTI-containing ART would be
wrongfully withheld from a large proportion of patients.
Vice versa, in a total of 17 patients experiencing
virological failure, only three harboured minority
NNRTI-resistant variants prior to ART.Discussion
We performed an investigation to test the hypothesis that
additional implementation of more sensitive assays for the
detection of minority drug-resistant HIV-1 variants in
routine clinical settings would prevent those few virologic
failures in treatment-naive patients who are initiating
ART with a NNRTI-containing regimen, although the
routine genotypic resistance test based on population
sequencing does not detect any NNRTI resistance
mutation. The SHCS reported low virologic failure
rates in patients receiving an NNRTI-containing, first-
line regimen: 45 out of 805 (6%) patients starting ART
between 1999 and 2005 [19]. Our most recent analysis,
including all patients between 1999 and 2006–2008,
showed no change in the rate of virologic failure
(84/1309; 6.4%). And our inclusion criteria, such as HIV-
1 subtype B or 01_AE, did not change this either
(26/471; 5.5%). Minority NNRTI-resistant HIV-1
variants were measured by AS-PCR in 208 randomly
chosen patients to determine whether more sensitive
genotypic resistance testing would have prevented those
virologic failures. Similar to the low rate of virologic
failure, the prevalence of preexisting minority NNRTI-
resistant HIV-1 variants was low. Yet, the observed
overlap was minimal, meaning that only two out of seven
patients with virologic failure harboured preexisting
minority NNRTI-resistant HIV-1 variants, whereas only
two out of 12 patients with preexisting minority
NNRTI-resistant HIV-1 variants experienced virologicpyright © Lippincott Williams & Wilkins. Unauthofailure. Minority M184V variants were irrelevant in
our cohort.
These results are contradictory to a pooled analysis of
10 studies [9] and a recent European multicohort case–
control study, both showing an increased risk of virologic
failure to first-line NNRTI-based ART when minority
drug-resistant HIV-1 variants were detected prior to ART
[11]. However, when separately examining each of these
studies included in the pooled analysis [9], it shows that all
four case–control studies resulted in a significant
association between virologic failure and preexisting
minority drug-resistant HIV-1 variants in ART-naive
individuals [10,20–22], but four of the included six cohort
studies did not reveal this association [23–26]. In terms of
the other two cohort studies, an association was found
when the mutational load was more than 2000 K103N
copies/ml plasma [27] or when all preexisting NNRTI-
resistance mutations were included in the analysis
independent of their frequency [28]. In the meantime,
three other cohort studies have been published and none of
them show an association between virologic failure and
preexisting minority drug-resistant HIV-1 variants in
ART-naive individuals [29–31]. This failure in detecting
an association could be due to the small number of
individuals included in most of the cohort studies (n< 100
in each study), but in the most recently published study,
more than 200 individuals were included [29].
By measuring only the K103N, Y181C and M184V
mutations, we might have missed other important and
maybe more predictive drug resistance mutations.
However, almost all analyses on the impact of preexisting
minority drug-resistant HIV-1 variants on NNRTI-
containing regimens are based on AS-PCR focusing
exactly on these three mutations, which are key drug
resistance mutations [9]. It might be possible to close this
gap by applying next-generation technologies, but this
technology has currently a lower sensitivity than AS-
PCR [32,33]. Noteworthy, expanding the spectrum of
measured drug resistance mutations would not change the
observation that most of the patients harbouring
preexisting minority NNRTI-resistant HIV-1 variants
were successfully treated with an NNRTI-containing
regimen. Thus, for those patients, NNRTIs would have
been wrongly withheld.
The mutational load, that is the absolute number of viruses
harbouring drug resistance mutations within the viral
population, might be more predictive for virologic failure
than the percentage of minority drug-resistant variants. It
has been shown that a preexisting mutational load of more
than 2000 K103N HIV-1 RNA copies/ml plasma,
quantified by AS-PCR specific for this mutation, is highly
predictive of virologic failure in patients starting with
a first-line, NNRTI-containing regimen [27]. Patient
13 harboured more than 20 000 K103N and more than
6000Y181C HIV-1RNA copies/ml plasma prior to ART,rized reproduction of this article is prohibited.
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Limited benefit of more sensitive genotypic resistance testing Metzner et al. 7whereas the mutational load was less than 2000 copies/ml
in all other patients. Also, in a recent pooled analysis of
almost 1000 patients, an increase of the mutational load was
associated with an increased riskof virologic failure, but the
risk increased already significantly at low mutational loads
of 10–99 copies/ml plasma [9].
We studied the impact of preexisting minority NNRTI-
resistant HIV-1 variants on the outcome of NNRTI-
containing, first-line ART in a retrospective manner.
Undoubtedly, a prospective study would be the ultimate
concept to proof or to deny the relevance of those minority
NNRTI-resistant HIV-1 variants on the outcome of first-
line regimens, particularly for treatments with a low
genetic barrier to resistance. But due to the low rate of
virologic failure, the low prevalence of preexisting
minority NNRTI-resistant HIV-1 variants in ART-naive
patients and a variety of other factors such as the numerous
possibilities of ART regimens, a huge number of patients
would need to be included in such a study.
Cost effectiveness was not explicitly analysed in our study.
Our data show that applying a more sensitive drug
resistance assay in 100 patients would have prevented one
virologic failure. However, in the case of preexisting
minority NNRTI-resistant HIV-1 variants, potentially
prevented failures have to be balanced against the costs of
NNRTI-sparing regimens, which often are more costly
and less often available as single tablet regimens. As
virologic failure did not occur in most of the patients with
preexisting minority NNRTI-resistant HIV-1 variants,
this suggests that standard pretreatment screening for
minority variants will not be the most cost-effective
option.
In summary, our study shows that preexisting K103N,
Y181C or M184V variants only have a very low positive
predictive value for ART-naive patients in routine clinical
settings wherein the rate of virologic failure is very low as
it is the case for the SHCS [34]. Hence, the number of
possibly preventable virologic failures in patients har-
bouring minority NNRTI-resistant HIV-1 variants was
small. Noteworthy, most virologic failures occurred
without evidence for preexisting minority NNRTI-
resistant HIV-1 variants, and in contrast, most of the
patients harbouring minority NNRTI resistant variants
did not experience virologic failure. Although per-
existing minority NNRTI-resistant HIV-1 variants may
have an impact on ART as revealed in settings of case–
control studies, the sole implementation of minority
NNRTI-resistant HIV-1 variant analysis in addition to
GRT cannot be recommended in routine clinical settings.
Additional associated cofactors need to be discovered.
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